Tenaya Therapeutics (TNYA) Cash from Operations (2020 - 2026)

Tenaya Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 19234000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 16.78% year-over-year to 19234000.0 in Q1 2026; TTM through Mar 2026 was 64386000.0, a 24.21% increase from a year earlier, with the FY2025 full-year figure at 68264000.0, up 24.57% from the prior year.
• Cash from Operations declined to 19234000.0 in Q1 2026 per TNYA's latest filing, from 13940000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 13940000.0 in Q4 2025 and bottomed at 30290000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 23112000.0 (2025), against an average of 22617352.94.
• Across the five-year window, Cash from Operations tumbled 111.58% in 2022 and soared 33.89% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 22682000.0 in 2022, then gained by 3.34% to 21924000.0 in 2023, then rose by 16.13% to 18388000.0 in 2024, then rose by 24.19% to 13940000.0 in 2025, then plunged by 37.98% to 19234000.0 in 2026.
• Per Business Quant, the three latest TNYA Cash from Operations figures stand at 19234000.0 (Q1 2026), 13940000.0 (Q4 2025), and 15599000.0 (Q3 2025).